Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose by Wariishi, Seiichiro et al.
1 
Postoperative administration of landiolol hydrochloride for patients with supraventricular 
arrhythmia: the efficacy of sustained intravenous infusion at a low dose 
 
Seiichiro Wariishi, 1,2 Koichi Yamashita, 3 Hideaki Nishimori, 1 
Takashi Fukutomi, 1 Masaki Yamamoto, 1 Geethalakshmi Radhakrishnan 1and Shiro Sasaguri 1 
 
1Department of Surgery II, Faculty of Medicine, Kochi University, Kochi, Japan 
2Intensive Care Unit, and 3Emergency Medicine, Kochi University Hospital, Kochi, Japan 
 
 
 
Address reprint requests to: Seiichiro Wariishi, MD: Department of Surgery II, Faculty of 
Medicine, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi 783-8505, Japan 
Tel: +81-88-880-2375 
Fax: +81-88-880-2376 
E-mail address: wari@kochi-u.ac.jp 
 
 
A summary of this study was introduced at the 38th Annual Meeting of the Japanese Society for 
Cardiovascular Surgery in February 2008, at Fukuoka. 
 
The word count of this manuscript is 1986 words. 
2 
Abstract 
The purpose of this study was to investigate the efficacy of landiolol hydrochloride, a 
short-acting 1 blocker, by initiating its administration at a low dose (5 g  kg-1  min-1) in 
patients with postoperative supraventricular arrhythmia. The efficacy of landiolol was evaluated 
in 38 patients who, after developing postoperative atrial flutter or fibrillation, with sinus 
tachycardia and 2 patients who had a history of paroxysmal atrial fibrillation with frequent atrial 
extrasystole. The heart rate and blood pressure before and 2 hours after the administration of 
landiolol were compared. A return to the sinus rhythm from supraventricular arrhythmia was 
noted in 89%. The heart rate was reduced from 137  26 bpm (before landiolol administration) to 
93  18 bpm (2 hours after the start of the medication, P < 0.01). As an agent to correct an 
arrhythmic condition, landiolol successfully raised the systolic blood pressure from 108  24 
mmHg (before medication) to 120  19 mmHg (2 hours after the medication was started, P < 
0.05).  Continuous intravenous infusion of landiolol at a low dose was found to be effective for 
postoperative supraventricular arrhythmia. 
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1. Introduction 
The perioperative care is necessarily conducted under unique conditions, such as excitation of 
the sympathetic nervous system, administration of agents to stimulate the circulatory system and 
systemic inflammatory responses [1,2] It has been found that  blockers are not only effective in 
controlling myocardial ischemia and arrhythmia but also in suppressing inflammatory cytokines 
and stabilizing intravascular plaques, [3-5] thus attracting further attention to their efficacy 
during perioperative care. In Japan, however, propranolol hydrochloride (hereafter abbreviated to 
propranolol) is the only  blocker that is currently available for intravenous administration, 
which was not always convenient for perioperative care because of its relatively long half-life [6].  
Landiolol hydrochloride (hereafter abbreviated to landiolol) is a short-acting 1 blocker that has 
been developed in Japan [7] Because of its extremely short half-life in blood (approximately 4 
minutes), [8] it appears to be highly promising as an agent in adjusting the timing of intravenous 
administration.  
In view of the efficacy of  blockers in the management of postoperative supraventricular 
arrhythmia, the current study was conducted employing landiolol. Based on the clinical results, 
administration at a low dose was initiated. 
 
2. Patients and Method 
The subjects were 40 patients (mean age, 70  9, range, range, 41 to 84 years; 30 men and 10 
women) who underwent continuous infusion of landiolol at a low dose during postoperative care 
at the Kochi University Hospital that started between April 2004 and December 2007. The group 
comprised those with: ischemic heart disease (12), valvular diseases (5), aortic diseases (9), 
respiratory tract diseases (5), digestive system diseases (7) and others (2) (Table 1). 
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Among those individuals who suffered from atrial flutter or fibrillation during the 
postoperative period, the following were selected as the subjects of the present study: 38 who 
failed in an attempt to correct the water-electrolyte balance and resisted the treatment of 50 mg of 
pilsicainide hydrochloride (hereafter abbreviated to pilsicainide) and 2 who had a history of 
paroxysmal atrial fibrillation and had began to develop frequent bouts of atrial extrasystole. 
Based on the clinical experience in the use of landiolol, a continuous intravenous infusion was 
started at a dose of 5 g  kg-1  min-1 for defibrillation; and depending on the heart rate and 
blood pressure, it was adjusted to approximately 2 g  kg-1  min-1 every 5 to 10 minutes. These 
patients suffered from the following clinical conditions: atrial fibrillation (28, with 2 maintaining 
the sinus rhythm after MAZE operation), atrial flutter (5), sinus tachycardia (5) and prophylaxis 
for paroxysmal atrial fibrillation (2). 
The heart rate and blood pressure before and 2 hours after the administration of landiolol 
were compared. 
Prior to medication, the expected outcome and the need of the treatment were fully explained 
to those 2 patients who were scheduled for the prevention of paroxysmal atrial fibrillation.   
The age, dosages, heart rate and blood pressure of the patients were recorded as a mean  
standard deviation. For statistical analysis, the Student’s-t-test was used with the significance 
level set at P < 0.05. 
 
3. Results 
 For the most patients, landiolol administration was started between days 2 and 5 after 
surgery (Fig. 1). Restoration of the normal sinus rhythm from supraventricular arrhythmia was 
noted in 34 of the 38 patients (89%). This effect was noted in 24 of the 28 patients (86%) of 
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those with atrial fibrillation and all of those with atrial flutter or sinus tachycardia. Subsequently, 
the heart rate was reduced from 137  26 bpm (before the start of landiolol administration) to 93 
 18 bpm (2 hours after the start of the medication, P < 0.01) (Fig. 2). As a consequence of 
antiarrhythmic treatment, the systolic blood pressure rose from 108  24 mmHg (before the start 
of landiolol administration) to 120  19 mmHg (2 hours after the start of the medication, P < 
0.05) (Fig. 3). The maximum dosage given was 7.5  7.6 g  kg-1  min-1. Reductions in the 
heart rate were noted even in the 2 patients who were treated for tachycardia associated with 
chronic atrial fibrillation. In one patient who developed an electrical storm in addition to 
postoperative atrial fibrillation, a complete atrioventricular block developed even at the dosage of 
1 g  kg-1  min-1 but cessation of medication restored the previous state. 
In both of the 2 patients who were treated to prevent paroxysmal atrial fibrillation, it was 
possible to maintain the sinus rhythm when landiolol administration was started when atrial 
extrasystoles repeatedly developed.  
 
4. Discussion 
Landiolol is outstanding in its immediate efficacy and adjustability [8]. Because of its high 
selectivity with 1 receptors, [6] it is readily administered to patients with respiratory tract 
diseases. Recently there have been occasional reports in which landiolol, with its outstanding 
adjustability, was found to be effective in the treatment of not only arrhythmia due to 
supraventricular tachycardia, [9] but also for correction of a left ventricular outflow tract 
obstruction [10,11] and amelioration of myocardial infarction [12]. In this country, the 
application of landiolol has been approved by National Health Insurance for the emergency 
treatment of intraoperative and postoperative arrhythmia due to supraventricular tachycardia 
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[13,14]. More recently, however, its clinical efficacy at a low dosage has been recognized. For 
the management of supraventricular arrhythmia, which is caused by surgical stress, the 
application of landiolol, a  blocker with an outstanding modulatory effect, is effective and 
therefore should be considered for inclusion in the therapeutic modalities. One of the reason why 
landiolol is advantageous to use is that in the advent an atrioventricular block, an adverse effect 
of the medication develops, the condition can be swiftly corrected by simply withdrawing the 
medication.  
As evidenced in the current study, landiolol restores the sinus rhythm at a very high 
frequency in cases of supraventricular arrhythmia. Combined with nicardipine, the efficacy of 
landiolol has also been reported for the antihypertensive therapy of aortic aneurysms and aortic 
dissection, perioperative care in left ventricular outflow tract obstruction and perioperative care 
of cases with myocardial ischemia [15]. Further increase in the indications for landiolol over 
wide clinical areas is expected. 
 
5. Conclusion 
Continuous intravenous infusion of landiolol at a low dose was found to be effective for 
postoperative supraventricular arrhythmia. Because it is a short-acting agent, the early treatment 
to suit to each clinical finding was possible. 
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Table 1 
Table 1 shows the background of patients who underwent continuous infusion of landiolol at a 
low dose during postoperative care 
Age (Years) 70±9 
Men/Women 30/10 
Primary disease  
Ischemic heart disease 12
Valvular diseases 5
Aortic diseases 9
Respiratory tract diseases 5
Digestive system diseases 7
Others 2
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Figure legends 
 
Fig. 1: The number of days after surgery when the medication was started (n=36) 
After the 7th day 
Op: surgery; POD: number of days after surgery. 
 
Fig. 2: Changes in heart rate (n=38) 
Before the start of landiolol administration 
2 hours after the start of landiolol administration 
○: heart rate;  *: comparison with the data before landiolol administration, P < 0.05. 
 
Fig. 3: Changes in blood pressure (n=38) 
Before the start of landiolol administration 
2 hours after the start of landiolol administration 
△ : systolic blood pressure; □: diastolic blood pressure; 
*: a comparison with the value before landiolol administration, P < 0.05. 



